// App-Quantinova.ai

581 : Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC

Researchers

Presenter

  • Sukhvinder Johal

Principal Investigators

  • Miguel Miranda

  • Tina Sarbajna

  • Xiaojin Shi

  • Alastair Greystoke

  • Melissa Johnson

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • The Newcastle Hospitals NHS Foundation Trust, Newcastle, UK

  • AstraZeneca, Cambridge, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ticilimumab

  • Durvalumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved